Comparison
Armodafinil vs Berberine
Side-by-side of Armodafinil and Berberine. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Armodafinil
Armodafinil is the R-enantiomer sold as Nuvigil. Half-life 10-15 h, 150 mg standard dose, narcolepsy and shift-work approvals, Schedule IV.
Berberine
Berberine supplement guide: 1500 mg/day lowers fasting glucose and HbA1c, AMPK activation, metformin parity in RCTs, dihydroberberine absorption.
Effects at a glance
Armodafinil
- •FDA approved in 2007 for narcolepsy, shift-work sleep disorder, and OSA residual sleepiness
- •R-enantiomer of modafinil; 150 mg armodafinil is roughly equivalent to 200 mg modafinil
- •Schedule IV controlled in the US; prescription-only globally
- •Longer terminal half-life of about 15 hours produces extended late-day wakefulness coverage
- •Same CYP3A4 induction as modafinil; reduces hormonal contraceptive efficacy
- •Side-effect profile and dermatologic risk warnings mirror modafinil
Berberine
- •Lowers HbA1c by ~0.7% versus placebo at 1500 mg/day across 27-trial meta-analysis (Lan 2015)
- •Roughly comparable to metformin on fasting glucose and HbA1c in small head-to-head RCTs (Yin 2008)
- •Reduces LDL cholesterol 10-20% and triglycerides 15-25% via PCSK9 inhibition
- •Activates AMPK, the cellular energy sensor that drives insulin-independent glucose uptake
- •Oral bioavailability under 1%; dihydroberberine is the higher-absorption alternative at lower doses
- •GI side effects affect 10-30% at 1500 mg/day; split dosing with meals reduces incidence
Side-by-side
| Attribute | Armodafinil | Berberine |
|---|---|---|
| Category | pharmaceutical | natural |
| Also known as | Nuvigil, R-modafinil, (R)-(-)-modafinil | berberine HCl, berberine hydrochloride |
| Half-life (hr) ↗ | 15 | 3 |
| Typical dose (mg) ↗ | 150 | 1500 |
| Dosing frequency | daily, morning | 3x daily with meals |
| Routes | oral | oral |
| Onset (hr) | 1 | 2 |
| Peak (hr) | 3 | 3 |
| Molecular weight | 273.35 | 336.36 |
| Molecular formula | C15H15NO2S | C20H18NO4+ |
| Mechanism | Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake systems; R-enantiomer of modafinil with longer half-life. | Activates AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and lipogenesis while increasing peripheral glucose uptake. Inhibits PCSK9 transcription, modulates bile acid signaling, and shifts gut microbiome composition. |
| Legal status | Schedule IV (US); prescription-only globally; not a supplement | Dietary supplement (US, EU, UK, Canada); Rx in some Asian jurisdictions |
| WADA status | banned | allowed |
| DEA / Rx | Schedule IV | Not scheduled |
| Pregnancy | Not recommended | Contraindicated (kernicterus risk in neonates) |
| CAS | 112111-43-0 | 2086-83-1 |
| PubChem CID | 9148206 | 2353 |
| Wikidata | Q4791953 | Q411435 |
Safety profile
Armodafinil
Common side effects
- headache
- nausea
- dizziness
- anxiety
- insomnia (with later-day dosing)
- dry mouth
- mild blood pressure elevation
Contraindications
- recent myocardial infarction
- unstable angina
- left ventricular hypertrophy
- significant arrhythmia
- history of Stevens-Johnson syndrome
- psychotic disorders
- pregnancy
- concurrent MAOI use
Interactions
- hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
- cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
- warfarin: CYP2C9 inhibition raises INR(moderate)
- phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
- MAOIs: potential hypertensive reaction(major)
- classical stimulants: additive cardiovascular and sleep-disruption effects(moderate)
Berberine
Common side effects
- constipation
- diarrhea
- abdominal cramping
- flatulence
- nausea
Contraindications
- pregnancy
- lactation
- neonatal jaundice
- severe liver disease
Interactions
- metformin: additive HbA1c reduction; additive GI side effects(moderate)
- insulin or sulfonylureas: additive hypoglycemia risk; dose adjustment may be required(major)
- statins (simvastatin, atorvastatin): CYP3A4 inhibition raises statin plasma levels(moderate)
- cyclosporine: raises cyclosporine levels through CYP3A4 and P-gp inhibition(major)
- calcium channel blockers (amlodipine): elevated plasma levels via CYP3A4 inhibition(moderate)
Which Should You Take?
Berberine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. Armodafinil is the right call when one of the conditionals below applies.
- → If your priority is wakefulness, pick Armodafinil.
- → If your priority is focus or working memory, pick Armodafinil.
- → If your priority is metabolic health and glucose control, pick Berberine.
- → If your priority is healthspan extension, pick Berberine.
Edge case: If you want to avoid controlled substance, Berberine is the more accessible choice.
Default choice: Berberine. Lower friction to source, and broader goal coverage. Reach for Armodafinil only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Armodafinil and Berberine?
Armodafinil and Berberine differ in category (pharmaceutical vs natural), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Armodafinil or Berberine?
Armodafinil half-life is 15 hours; Berberine half-life is 3 hours.
Can you stack Armodafinil with Berberine?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper